aMoon expands investment in BiondVax
The life sciences venture capital fund could become the controlling shareholder in universal flu vaccine developer Biondvax after the company's rights issue.
Teva CFO: We'll defend ourselves vigorously
Speaking at an Oppenheimer conference, Teva's Mike McClellan said the price-fixing allegations in the US were not new, and went on to describe the company's growth engines.
The times they are a-changing us
Prof. Irad Ben-Gal talks to "Globes" about dual digital and physical existence, and other ways technology will challenge our present assumptions about human life.